Logo image of ALAB

ASTERA LABS INC (ALAB) Stock Fundamental Analysis

USA - NASDAQ:ALAB - US04626A1034 - Common Stock

157.51 USD
+1.2 (+0.77%)
Last: 10/21/2025, 8:00:00 PM
158.93 USD
+1.42 (+0.9%)
Pre-Market: 10/22/2025, 6:34:47 AM
Fundamental Rating

5

Overall ALAB gets a fundamental rating of 5 out of 10. We evaluated ALAB against 112 industry peers in the Semiconductors & Semiconductor Equipment industry. While ALAB has a great health rating, its profitability is only average at the moment. ALAB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ALAB was profitable.
In the past year ALAB had a positive cash flow from operations.
ALAB Yearly Net Income VS EBIT VS OCF VS FCFALAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of 7.88%, ALAB is in the better half of the industry, outperforming 77.68% of the companies in the same industry.
ALAB has a better Return On Equity (8.82%) than 70.54% of its industry peers.
ALAB has a Return On Invested Capital of 2.87%. This is comparable to the rest of the industry: ALAB outperforms 55.36% of its industry peers.
Industry RankSector Rank
ROA 7.88%
ROE 8.82%
ROIC 2.87%
ROA(3y)-16.28%
ROA(5y)N/A
ROE(3y)-19.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALAB Yearly ROA, ROE, ROICALAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -10 -20 -30

1.3 Margins

With a decent Profit Margin value of 16.54%, ALAB is doing good in the industry, outperforming 75.00% of the companies in the same industry.
With a decent Operating Margin value of 6.99%, ALAB is doing good in the industry, outperforming 61.61% of the companies in the same industry.
The Gross Margin of ALAB (75.52%) is better than 95.54% of its industry peers.
Industry RankSector Rank
OM 6.99%
PM (TTM) 16.54%
GM 75.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALAB Yearly Profit, Operating, Gross MarginsALAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALAB is destroying value.
ALAB has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ALAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALAB Yearly Shares OutstandingALAB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 50M 100M 150M
ALAB Yearly Total Debt VS Total AssetsALAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 117.23 indicates that ALAB is not in any danger for bankruptcy at the moment.
ALAB has a better Altman-Z score (117.23) than 99.11% of its industry peers.
There is no outstanding debt for ALAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 117.23
ROIC/WACC0.25
WACC11.58%
ALAB Yearly LT Debt VS Equity VS FCFALAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

ALAB has a Current Ratio of 11.10. This indicates that ALAB is financially healthy and has no problem in meeting its short term obligations.
ALAB has a better Current ratio (11.10) than 96.43% of its industry peers.
A Quick Ratio of 10.55 indicates that ALAB has no problem at all paying its short term obligations.
ALAB's Quick ratio of 10.55 is amongst the best of the industry. ALAB outperforms 97.32% of its industry peers.
Industry RankSector Rank
Current Ratio 11.1
Quick Ratio 10.55
ALAB Yearly Current Assets VS Current LiabilitesALAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ALAB have decreased strongly by -269.05% in the last year.
The Revenue has grown by 242.24% in the past year. This is a very strong growth!
EPS 1Y (TTM)-269.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%238.46%
Revenue 1Y (TTM)242.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%149.74%

3.2 Future

The Earnings Per Share is expected to grow by 44.77% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALAB will show a very strong growth in Revenue. The Revenue will grow by 55.92% on average per year.
EPS Next Y61.56%
EPS Next 2Y44.35%
EPS Next 3Y44.77%
EPS Next 5YN/A
Revenue Next Year103.49%
Revenue Next 2Y66.08%
Revenue Next 3Y55.92%
Revenue Next 5YN/A

3.3 Evolution

ALAB Yearly Revenue VS EstimatesALAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 500M 1B
ALAB Yearly EPS VS EstimatesALAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 1 2 3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 114.97, the valuation of ALAB can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ALAB is on the same level as its industry peers.
When comparing the Price/Earnings ratio of ALAB to the average of the S&P500 Index (27.77), we can say ALAB is valued expensively.
A Price/Forward Earnings ratio of 75.59 indicates a quite expensive valuation of ALAB.
ALAB's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. ALAB is more expensive than 60.71% of the companies in the same industry.
ALAB's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.23.
Industry RankSector Rank
PE 114.97
Fwd PE 75.59
ALAB Price Earnings VS Forward Price EarningsALAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALAB is on the same level as its industry peers.
ALAB's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 124.45
EV/EBITDA 519.08
ALAB Per share dataALAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ALAB does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as ALAB's earnings are expected to grow with 44.77% in the coming years.
PEG (NY)1.87
PEG (5Y)N/A
EPS Next 2Y44.35%
EPS Next 3Y44.77%

More info and screens

0

5. Dividend

5.1 Amount

ALAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTERA LABS INC

NASDAQ:ALAB (10/21/2025, 8:00:00 PM)

Premarket: 158.93 +1.42 (+0.9%)

157.51

+1.2 (+0.77%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04
Inst Owners73.13%
Inst Owner Change0.37%
Ins Owners12.78%
Ins Owner Change-6.25%
Market Cap26.18B
Analysts81.74
Price Target189.82 (20.51%)
Short Float %6.65%
Short Ratio1.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.57%
Min EPS beat(2)13.95%
Max EPS beat(2)33.19%
EPS beat(4)4
Avg EPS beat(4)29.89%
Min EPS beat(4)13.95%
Max EPS beat(4)40.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.57%
Min Revenue beat(2)2.08%
Max Revenue beat(2)9.05%
Revenue beat(4)4
Avg Revenue beat(4)8.25%
Min Revenue beat(4)2.08%
Max Revenue beat(4)13.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.62%
PT rev (3m)84.66%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)15.65%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)17.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)14.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.33%
Valuation
Industry RankSector Rank
PE 114.97
Fwd PE 75.59
P/S 43.24
P/FCF 124.45
P/OCF 105.11
P/B 23.05
P/tB 23.05
EV/EBITDA 519.08
EPS(TTM)1.37
EY0.87%
EPS(NY)2.08
Fwd EY1.32%
FCF(TTM)1.27
FCFY0.8%
OCF(TTM)1.5
OCFY0.95%
SpS3.64
BVpS6.83
TBVpS6.83
PEG (NY)1.87
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.88%
ROE 8.82%
ROCE 3.63%
ROIC 2.87%
ROICexc 33.44%
ROICexgc 33.44%
OM 6.99%
PM (TTM) 16.54%
GM 75.52%
FCFM 34.74%
ROA(3y)-16.28%
ROA(5y)N/A
ROE(3y)-19.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 891.87%
Cap/Sales 6.39%
Interest Coverage 250
Cash Conversion 533.97%
Profit Quality 210.04%
Current Ratio 11.1
Quick Ratio 10.55
Altman-Z 117.23
F-Score7
WACC11.58%
ROIC/WACC0.25
Cap/Depr(3y)573.57%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-269.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%238.46%
EPS Next Y61.56%
EPS Next 2Y44.35%
EPS Next 3Y44.77%
EPS Next 5YN/A
Revenue 1Y (TTM)242.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%149.74%
Revenue Next Year103.49%
Revenue Next 2Y66.08%
Revenue Next 3Y55.92%
Revenue Next 5YN/A
EBIT growth 1Y-293.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year199.96%
EBIT Next 3Y77.16%
EBIT Next 5YN/A
FCF growth 1Y761.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1174.83%
OCF growth 3YN/A
OCF growth 5YN/A